Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Inhibitor of apoptosis as a therapeutic vulnerability in high-fatality leukemia

EF 2021-22

Résumé
Acute Megakaryoblastic Leukemia (AMKL) is a subtype of Acute Myeloid Leukemia (AML) and is found in around 10% of children suffering from AML. Patients of childhood AMKL are at a higher risk of responding poorly to chemotherapy, early relapse and poor survival rates (40% of cure rates). AMKL can be subgrouped based on the abnormal chimeric fusion protein it carries which is thought to be the cause for leukemia. Our lab successfully generated models of some of these rare but relevant high-fatality AMKL. These synthetic models of AMKL are able to mimic the human disease in a patho-physiological relevant context in mice. We used these models in a high-throughput chemical screen to identify new treatment options and found two drugs that specifically target only one subgroup of AMKL. Both drugs are targeting proteins that are involved in programmed cell death, also known as apoptosis. The goal of my project is to analyse the impact of those two drugs on my leukemic cells. Briefly, I will analyse what effect our drugs have on our models of AMKL by observing various parameters including if they undergo cell death or irreversible growth arrest. Furthermore, I will study if they are becoming more mature after drug treatment and lose their potential to initiate leukemia. Additionally, I will investigate if the proposed drugs are using the published mechanism of action in our models of AMKL. Importantly, I will monitor for each assay if these two drugs are impacting healthy stem and progenitor cells. Overall, this project will highlight the importance of apoptosis for different subgroups of AMKL and identify new therapeutic options that can be exploited for high-risk patients of childhood leukemia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466931
Name
Fatima Furat
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Inhibitor of apoptosis as a therapeutic vulnerability in high-fatality leukemia
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Megakaryoblastic Leukemia (Amkl); Apoptosis; Cbfa2t3-Glis2; Chemogenomic Screen; Childhood Leukemia; Drug Discovery; Nup98-Kdm5a; Oncogenic Fusion Proteins; Synthetic Leukemia Models; Targeted Therapies
Abstract
Acute Megakaryoblastic Leukemia (AMKL) is a subtype of Acute Myeloid Leukemia (AML) and is found in around 10% of children suffering from AML. Patients of childhood AMKL are at a higher risk of responding poorly to chemotherapy, early relapse and poor survival rates (40% of cure rates). AMKL can be subgrouped based on the abnormal chimeric fusion protein it carries which is thought to be the cause for leukemia. Our lab successfully generated models of some of these rare but relevant high-fatality AMKL. These synthetic models of AMKL are able to mimic the human disease in a patho-physiological relevant context in mice. We used these models in a high-throughput chemical screen to identify new treatment options and found two drugs that specifically target only one subgroup of AMKL. Both drugs are targeting proteins that are involved in programmed cell death, also known as apoptosis. The goal of my project is to analyse the impact of those two drugs on my leukemic cells. Briefly, I will analyse what effect our drugs have on our models of AMKL by observing various parameters including if they undergo cell death or irreversible growth arrest. Furthermore, I will study if they are becoming more mature after drug treatment and lose their potential to initiate leukemia. Additionally, I will investigate if the proposed drugs are using the published mechanism of action in our models of AMKL. Importantly, I will monitor for each assay if these two drugs are impacting healthy stem and progenitor cells. Overall, this project will highlight the importance of apoptosis for different subgroups of AMKL and identify new therapeutic options that can be exploited for high-risk patients of childhood leukemia.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fatima, Furat
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~